European Medicines Agency Launches Safety Review of Injectable Iron Drugs

The European Medicines Agency (EMA) has launched a safety review of all injectable iron-containing medicines following reports of serious side effects, including dangerously low blood phosphate levels and bone softening.

The agency's Pharmacovigilance Risk Assessment Committee (PRAC) initiated the review on Friday to assess the overall risk-benefit profile of these widely used treatments for iron deficiency.

Scope of the Investigation

The review was triggered by reports suggesting that current measures to mitigate risks associated with ferric carboxymaltose, a common active substance in these drugs, may be insufficient. According to the EMA, these reports included serious cases of hypophosphatemia (low blood phosphate) and osteomalacia (bone softening), some occurring after only one or two doses.

While prompted by issues with a specific substance, the committee has expanded its investigation to cover all injectable iron products. The EMA noted that similar adverse events have been reported with medicines containing different active iron ingredients.

Ad

Regulatory Context and Market Implications

This action in Europe follows a recent decision by the U.S. Food and Drug Administration (FDA), which added a boxed warning—its most serious type—to the labels of ferric carboxymaltose injections, highlighting the same risks.

The coordinated scrutiny from major global regulators could have significant implications for manufacturers of these drugs. The EMA's committee will determine if changes are required for the products' marketing authorizations, which could include updated warnings or restrictions on use.

Injectable iron medicines are critical for treating iron-deficiency anemia in patients for whom oral supplements are ineffective or cannot be tolerated, or when rapid iron restoration is medically necessary. Any new restrictions could impact treatment protocols for this patient population.